➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Medtronic
Express Scripts
McKesson
AstraZeneca

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRILLIANT BLUE G

« Back to Dashboard

All Clinical Trials for Brilliant Blue G

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00738413 Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both Unknown status Weill Medical College of Cornell University Phase 1/Phase 2 2008-08-01 Subjects with thalassemia major require regular transfusion therapy to sustain life. The iron present in the transfused blood remains in the body where it can cause a variety of organ dysfunctions. Lifelong iron chelation therapy is needed to maintain iron balance but its effectiveness varies greatly. Like that of deferoxamine (Desferal, DFO) the mainstay of chelation therapy for 30 years, the effectiveness of deferasirox (Exjade, ICL670), the newly approved, orally effective iron chelating drug, is not satisfactory in all subjects. Even with good compliance, the iron excretion induced by a given drug exhibits wide subject-to-subject variability. There is often persistent iron overload of extra hepatic tissues such as the heart and pancreas leading to cardiac disease and diabetes. Combining the drugs may be a better approach in those subjects at increased risk. The iron balance studies proposed will permit an assessment of the potential of such a combination to place subjects in net negative iron balance and the relative effectiveness of the combination in relation to that of the individual drugs, an additive effect being expected. With such information, physicians will be able to design individualized chelation regimens that maximize effectiveness while minimizing side effects by adjusting the ratio and/or the dosing schedule of the two drugs.
NCT01718314 Comparison of Sublingual Misoprostol Versus Lidocaine Spray for Hysteroscopy Completed Dr. Sami Ulus Children's Hospital N/A 2008-03-01 Hysteroscopy is an instrument to visualize the interior walls of uterus (womb) and it enables the doctor to do minor operative procedures. Although it causes little discomfort, sometimes it may be disturbing for the patient. This pain is usually perceived during the passage of the instrument through the cervix (neck of the womb). The investigators would like to minimize this pain by two drugs: Misoprotol and lidocaine
NCT01820520 Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery Unknown status Asociación para Evitar la Ceguera en México Phase 3 2013-01-01 Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography, pattern reversal electroretinogram and multifocal electroretinogram.
NCT02052219 BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn Anthera Pharmaceuticals Phase 3 2014-10-01 The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.
NCT03020459 Internal Limiting Membrane Peeling-reposition to Treat Idiopathic Macular Holes Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine N/A 2017-01-01 To compare the morphologic and functional outcomes of internal limiting membrane peeling-reposition versus peeling in idiopathic macular holes
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brilliant Blue G

Condition Name

Condition Name for Brilliant Blue G
Intervention Trials
Macular Hole 2
IgA Nephropathy 1
Gingivitis 1
Thalassemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brilliant Blue G
Intervention Trials
Retinal Perforations 2
Gingivitis 1
Kidney Diseases 1
Glomerulonephritis, IGA 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brilliant Blue G

Trials by Country

Trials by Country for Brilliant Blue G
Location Trials
China 1
Mexico 1
Turkey 1
Canada 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brilliant Blue G
Location Trials
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brilliant Blue G

Clinical Trial Phase

Clinical Trial Phase for Brilliant Blue G
Clinical Trial Phase Trials
Phase 3 2
Phase 1/Phase 2 1
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brilliant Blue G
Clinical Trial Phase Trials
Completed 2
Unknown status 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brilliant Blue G

Sponsor Name

Sponsor Name for Brilliant Blue G
Sponsor Trials
Church & Dwight Company, Inc. 1
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 1
Anthera Pharmaceuticals 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brilliant Blue G
Sponsor Trials
Other 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Colorcon
Baxter
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.